Capstone Green Energy Corp Stock (OTC: CGRNQ)

Capstone Green Energy Corp (OTC:CGRNQ) Stock, Quote.Headers.trade-ideas

Capstone Green Energy Corp

<a href="https://www.forexlive.com/centralbank/feds-kashari-says-a-lot-of-progress-made-on-inflation-labor-market-is-strong-20241014/" title="https://www.forexlive.com/centralbank/feds-kashari-says-a-lot-of-progress-made-on-inflation-labor-market-is-strong-20241014/">https://www.forexlive.com/centralbank/feds-kashari-says-a-lot-of-progress-made-on-inflation-labor-market-is-strong-20241014/</a>

Macro Economic Events

News

Economics

Federal Reserve

Fed's Kashkari Says We've Made A Lot Of Progress On Inflation, And Labor Market Is Strong; Not Worth It To Have Unemployment Rate Shoot Up; Don't Think China Is Remotely Competitive With U.S.; Not At All Worried That Yuan Could Replace Dollar As Global Reserve Currency; U.S. Competitive Position Is Very Very Strong, Though Can't Take It For Granted

INVO BioScience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares soared Monday after the company announced it closed <a href="https://www.benzinga.com/pressreleases/24/10/g41312767/invo-bioscience-and-naya-biosciences-close-merger-combined-company-to-operate-as-naya-biosciences-">its merger with NAYA Biosciences. </a>
The Details: Invo BioScience said the combined company will continue to operate its fertility business as well as expand its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The company expects to change its name to Naya Biosciences and trade on the Nasdaq under the &#8220;NAYA&#8221; ticker.&nbsp;
The combined company will be led by Invo CEO Steve Shum, Invo CFO Andrea Goren and Dr. Daniel Teper, founder and former CEO of Naya Biosciences, who will be appointed as president of the combined company and CEO of the Naya Therapeutics subsidiary.&nbsp;
Read Next: <a href="https://www.benzinga.com/fintech/24/10/41295297/whats-going-on-with-sofi-technologies-stock">What&#8217;s Going On With SoFi Technologies Stock?</a>
&#8220;We are confident that our expanded portfolio business model and combined assets have the potential to create significant value for both legacy and new shareholders,&#8221; said Steve Shum, CEO of the combined company.
&#8220;Combining scalable, profitable revenues from our fertility business with the upside of innovative therapeutics optimizes risk-return for investors. In addition, the hub-and-spoke model allows for shared resources and talent to accelerate the development of our lean, agile subsidiaries," Shum said.&nbsp;
Invo shares climbed on heavy trading volume following Monday's announcement with more than 54 million shares traded in the session, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.&nbsp;
INVO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Invo BioScience shares are up 1.61% after-hours at $1.24 after gaining 92.55% in Monday&#8217;s regular session.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41277250/whats-going-on-with-first-solar-stock">What&#8217;s Going On With First Solar Stock?</a></li>
</ul>
Photo: Shutterstock&nbsp;

Health Care

Crowdsourcing

Movers

INVO

What Happened With Invo BioScience Stock Today?

Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has outperformed the market over the past 15 years by 24.28% on an annualized basis producing an average annual return of 36.11%. Currently, Netflix has a market capitalization of $306.28 billion. 
Buying $100 In NFLX: If an investor had bought $100 of NFLX stock 15 years ago, it would be worth $10,022.09 today based on a price of $713.67 for NFLX at the time of writing.
<h3>Netflix's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728941426_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

NFLX

Here's How Much $100 Invested In Netflix 15 Years Ago Would Be Worth Today

EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) has outperformed the market over the past 20 years by 2.05% on an annualized basis producing an average annual return of 10.7%. Currently, EOG Resources has a market capitalization of $74.42 billion. 
Buying $1000 In EOG: If an investor had bought $1000 of EOG stock 20 years ago, it would be worth $7,702.94 today based on a price of $130.89 for EOG at the time of writing.
<h3>EOG Resources's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728941421_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $7,700 Today

ATEK

Athena Technology Acquisition Corp. II Says Financial Statements Contained Audit Opinion That Included Explanatory Paragraph Related To Ability To Continue As Going Concern

The text of the letter included:
Over much of the past two years, Medical Properties Trust has been the target of considerable scrutiny from short-selling hedge funds as well as certain media outlets.
In response to certain claims asserted by Viceroy Research, the Board&#39;s Audit Committee engaged Wachtell Lipton in early 2023 to conduct an independent investigation into the short-seller allegations, including with respect to MPT transactions involving Steward Healthcare beginning in 2016.
Wachtell Lipton in turn retained a leading global consulting firm to assist with financial forensics as part of this investigation. No limitations or restrictions were placed on the scope of the investigation and management cooperation with the investigation was exemplary.
The key findings from the investigation are as follows:
<ol>
<li>The investigation identified no evidence that MPT gratuitously overpays its operator-tenants for real estate.</li>
<li>The investigation identified no evidence of improper round-tripping.</li>
<li>The investigation found no evidence of improper recognition of &quot;uncollectable&quot; rent through GAAP-mandated straight-line revenue recognition. The investigation also found no evidence to substantiate the allegation that MPT was required to consolidate Steward&#39;s financial results.</li>
<li>The investigation concluded that neither Manolete Health nor MPT has an ownership interest in any Malta property or hospital.</li>
<li>The investigation yielded no evidence that management manipulated acquisitions or other metrics to meet compensation targets.</li>
<li>The investigation yielded no evidence of concerns regarding management integrity.</li>
</ol>

Medical Properties Trust Releases Letter To Shareholders Regarding Findings Of Independent, Forensic Investigation Into Short-seller Allegations; Says Board Continues To Stand Firmly Behind Its Management Team

Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares popped in afternoon trading Monday after Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) announced intentions to purchase power from <a href="https://www.benzinga.com/topic/nuclear-energy">small modular reactor (SMR) developer Kairos Power</a>.
What Happened: Google on Monday said it would purchase power from a fleet of SMRs made by Kairos as the company and other tech giants increasingly turn to nuclear for energy needs related to the <a href="http://benzinga.com/topic/ai">AI</a> revolution, per <a href="https://www.cnbc.com/2024/10/14/google-inks-deal-with-nuclear-company-as-data-center-power-demand-surges.html">CNBC</a>.
&#8220;We believe that nuclear energy has a critical role to play in supporting our clean growth and helping to deliver on the progress of AI,&#8221; Michael Terrell, senior director for energy and climate at Google, reportedly told reporters. 
&#8220;The grid needs these kinds of clean, reliable sources of energy that can support the build-out of these technologies,&#8221; Terrell said. &#8220;We feel like nuclear can play an important role in helping to meet our demand, and helping meet our demand cleanly, in a way that's more around the clock.&#8221;
Big tech companies are increasingly looking to nuclear power to meet the rising energy demands of data centers. Data centers need to have reliable power at all times and nuclear offers an emissions-free option. Many hyperscalers also have emissions-reduction goals that they are trying to meet.
Google plans to have its first reactor online by 2030, with more reactors expected to follow through 2035. 
"It is an incredibly promising bet, and one that, you know, if we can get these projects to scale and then scale globally, will deliver enormous benefits to communities and power grids around the world," Terrell said.
See Also: <a href="https://www.benzinga.com/news/24/10/41309060/nvidias-jensen-huang-says-chatgpt-led-to-awakening-of-ai-praises-sam-altmans-openai-as-one-of-most-c">Nvidia&#8217;s Jensen Huang Says ChatGPT Led To &#8216;Awakening Of AI,&#8217; Praises Sam Altman&#8217;s OpenAI As One Of Most Consequential Companies Of Our Time</a>
The Google news helped lift nuclear stocks across the board on Monday, but Oklo was among the biggest gainers. Investors may be speculating that Oklo could be one of the next companies to ink a deal with a big tech player, given the company&#8217;s ties to OpenAI and Sam Altman. 
Oklo went public in May through a merger with <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37906984/sam-altmans-under-the-radar-spac-fuses-ai-expertise-with-nuclear-energy-here-are-the-oth">AltC Acquisition Corp</a>, a special purpose acquisition company (SPAC) backed by Altman, who has also been the chair of Oklo&#8217;s board since 2015. Oklo is the only public company that Altman chairs.
Given Altman&#8217;s involvement with Oklo and OpenAI&#8217;s leadership in the AI space, it wouldn&#8217;t be surprising to see the companies work together in some capacity to meet rising energy demand. 
OpenAI&nbsp;recently <a href="https://www.benzinga.com/news/24/10/41149788/openai-valuation-soars-to-157b-in-latest-funding-round">secured new funding</a> at a valuation of $157 billion&nbsp;from investors including Nvidia, Microsoft, Thrive Capital, SoftBank and Ark Funds.
OKLO Price Action:&nbsp;<a href="http://benzinga.com/quote/oklo" target="_blank" rel="noreferrer noopener">Oklo shares</a>&nbsp;closed Monday up at 9.73%. The stock was up another 3.78% in after-hours, trading at $10.42, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of Oklo.

After-Hours Center

Tech

GOOG

GOOGL

OKLO

Sam Altman's Oklo Jumps On Google Nuclear Deal: What's Going On?

Arm Holdings PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) has seen gains over the past week. Here&#8217;s <a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41185402/arm-stock-softbanks-ai-goals-vs-bearish-market-trends">what you need to know.</a>
What To Know: The demand for semiconductors has grown, driven by advancements in artificial intelligence and mobile technology. Arm's technology is a critical component in devices such as smartphones and cloud services. Additionally, the partnership with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) for the iPhone 16 may have also influenced investor confidence in the company.
Financially, Arm reported record revenue of $939 million for Fiscal year 2025, representing a 39% increase from the previous year. The gross margin stands at 96.5%, with licensing revenue growing by 72%. Currently, Arm is trading within a 52-week range of $46.50 to $188.75. The session volume reached 8.942 million shares, exceeding the 100-day average volume of 7.928 million shares.
The stock is also trending on social media such as Yahoo Finance and StockTwits, attracting increased investor attention and engagement.
ARM Price Action: Arm Holdings shares were up by 6.84% at $162.82 at market close Monday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-1024x532.png" alt="" class="wp-image-594802" style="width:494px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM.png 1456w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/24/10/41320620/unitedhealth-group-q3-earnings-preview-dow-jones-industrial-average-stock-could-move-marke">UnitedHealth Group Q3 Earnings Preview: Dow Jones Industrial Average Stock Could &#8216;Move Markets&#8217; Tuesday</a></li>
</ul>
Photo: Shutterstock.

AAPL

Arm Holdings Stock Climbs In A Week As Semiconductor Sector Strengthens

– Engineering Union Spokesperson

Management

Boeing To Send 60-Day Notices In Mid November To Staff Being Made Redundant As Part Of Sweeping Job Cuts

-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- &nbsp;
-- National Reimbursement Payment Determination from CMS for its PoNS Controller Deferred to the Next Cycle --
NEWTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) posted final Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies fee schedule payment rates for the PoNS Mouthpiece (HCPCS code A4594) at $2,963.30 to be implemented January 1, 2025 and deferred final national determination of the payment rate for the PoNS Controller (HCPCS Code A4593) to the next payment cycle.

HSDT

Helius Medical Technologies Announces Reimbursement Determination For PoNs Mouthpiece Set At $2,963.30 On Lump Sum Payment To Be Challenged By Co; Disagrees With CMS' Methods, Pricing & Deferral For Determining Payment Rates For PoNs Mouthpiece & Pons Controller

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $128.22, a high estimate of $143.00, and a low estimate of $120.00. Marking an increase of 4.61%, the current average surpasses the previous average price target of $122.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939648_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Abbott Laboratories among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$129.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$131.00</td>
<td>-</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Abbott Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Abbott Laboratories's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Abbott Laboratories's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>Discovering Abbott Laboratories: A Closer Look</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Key Indicators: Abbott Laboratories's Financial Health</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Abbott Laboratories showcased positive performance, achieving a revenue growth rate of 4.0% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Abbott Laboratories's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.55%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Abbott Laboratories's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.33% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Abbott Laboratories's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.79%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Abbott Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 9 Analysts Discuss Abbott Laboratories Stock

In the last three months, 5 analysts have published ratings on Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $22.50 and a low estimate of $22.50. This current average has not changed from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939642_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Betterware de Mexico SAPI. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Betterware de Mexico SAPI's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Betterware de Mexico SAPI's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Betterware de Mexico SAPI analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Betterware de Mexico SAPI</h2>
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
<h3>Betterware de Mexico SAPI's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Betterware de Mexico SAPI showcased positive performance, achieving a revenue growth rate of 5.26% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 19.61%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.75%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 3.46, Betterware de Mexico SAPI adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWMX

Assessing Betterware de Mexico SAPI: Insights From 5 Financial Analysts

Across the recent three months, 9 analysts have shared their insights on iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $110.67, a high estimate of $145.00, and a low estimate of $78.00. A 16.79% drop is evident in the current average compared to the previous average price target of $133.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939633_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of iRhythm Technologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Allen Gong</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$117.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$119.00</td>
<td>$138.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to iRhythm Technologies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of iRhythm Technologies compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of iRhythm Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into iRhythm Technologies's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IRTC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on iRhythm Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind iRhythm Technologies</h2>
iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.
<h3>Breaking Down iRhythm Technologies's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: iRhythm Technologies displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 19.27%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: iRhythm Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -13.58% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): iRhythm Technologies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -21.22%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): iRhythm Technologies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 7.43, iRhythm Technologies faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IRTC

Beyond The Numbers: 9 Analysts Discuss iRhythm Technologies Stock

Across the recent three months, 7 analysts have shared their insights on Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $80.43, with a high estimate of $93.00 and a low estimate of $77.00. This upward trend is evident, with the current average reflecting a 6.43% increase from the previous average price target of $75.57.
<img src="https://www.benzinga.com/files/images/story/2024/1728939625_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Globus Medical among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$79.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Globus Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Globus Medical compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Globus Medical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Globus Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GMED/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Globus Medical analyst ratings.</a>
<h2>Get to Know Globus Medical Better</h2>
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
<h3>Breaking Down Globus Medical's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Globus Medical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 115.93% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Globus Medical's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 5.04%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Globus Medical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.8%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.64%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Globus Medical's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GMED

The Analyst Verdict: Globus Medical In The Eyes Of 7 Experts

Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) is preparing to release its quarterly earnings on Tuesday, 2024-10-15. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Bank of America to report an earnings per share (EPS) of $0.77.
Anticipation surrounds Bank of America's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.03, leading to a 0.34% drop in the share price the following trading session.
Here's a look at Bank of America's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.80</td>
<td>0.77</td>
<td>0.63</td>
<td>0.81</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.83</td>
<td>0.83</td>
<td>0.70</td>
<td>0.90</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1728939618_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Bank of America were trading at $41.95 as of October 11. Over the last 52-week period, shares are up 51.74%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/BAC/earnings">To track all earnings releases for Bank of America visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

A Glimpse of Bank of America's Earnings Potential

Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) has outperformed the market over the past 5 years by 19.96% on an annualized basis producing an average annual return of 34.38%. Currently, Wingstop has a market capitalization of $11.69 billion. 
Buying $100 In WING: If an investor had bought $100 of WING stock 5 years ago, it would be worth $438.32 today based on a price of $399.05 for WING at the time of writing.
<h3>Wingstop's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728939617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WING

$100 Invested In Wingstop 5 Years Ago Would Be Worth This Much Today

During the last three months, 13 analysts shared their evaluations of AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $10.23, a high estimate of $14.00, and a low estimate of $7.00. Highlighting a 22.79% decrease, the current average has fallen from the previous average price target of $13.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939617_0_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of AvidXchange Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Dominick Gabriele</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$9.00</td>
<td>$11.50</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$11.00</td>
<td>$13.50</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AvidXchange Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AvidXchange Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of AvidXchange Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AvidXchange Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AVDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AvidXchange Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind AvidXchange Holdings</h2>
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
<h3>Unraveling the Financial Story of AvidXchange Holdings</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, AvidXchange Holdings showcased positive performance, achieving a revenue growth rate of 15.33% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: AvidXchange Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 0.41%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AvidXchange Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.06%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): AvidXchange Holdings's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.02%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: AvidXchange Holdings's debt-to-equity ratio is below the industry average at 0.21, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AVDX

Expert Outlook: AvidXchange Holdings Through The Eyes Of 13 Analysts

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) has outperformed the market over the past 10 years by 1.27% on an annualized basis producing an average annual return of 12.92%. Currently, AECOM has a market capitalization of $14.26 billion. 
Buying $1000 In ACM: If an investor had bought $1000 of ACM stock 10 years ago, it would be worth $3,498.68 today based on a price of $106.36 for ACM at the time of writing.
<h3>AECOM's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728939612_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In AECOM 10 Years Ago Would Be Worth This Much Today

During the last three months, 7 analysts shared their evaluations of Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $12.71, a high estimate of $17.00, and a low estimate of $10.00. Highlighting a 1.17% decrease, the current average has fallen from the previous average price target of $12.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939609_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Coty among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$10.50</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$16.50</td>
</tr>
<tr>
<td>Robert Ottenstein</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Coty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Coty compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Coty's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Coty's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/COTY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Coty analyst ratings.</a>
<h2>Unveiling the Story Behind Coty</h2>
Coty is a global beauty maker that focuses on fragrance (59% of sales) and color cosmetics (28%), with limited exposure to skincare (5%) and body care (8%). For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein, while its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrities Kim Kardashian and Kylie Jenner to launch makeup products bearing their names. By region, Coty generates close to 44% of sales from Europe, 42% from the Americas, and 14% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 53% stake.
<h3>Coty's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Coty's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.87% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -7.35%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Coty's ROE excels beyond industry benchmarks, reaching -2.56%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Coty's ROA stands out, surpassing industry averages. With an impressive ROA of -0.82%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Coty's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.08, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COTY

Analyst Scoreboard: 7 Ratings For Coty

<a href="https://www.washingtonpost.com/world/2024/10/14/israel-iran-strike-nuclear-oil-military/">https://www.washingtonpost.com/world/2024/10/14/israel-iran-strike-nuclear-oil-military/</a>
&nbsp;
TEL AVIV — Israeli Prime Minister Benjamin Netanyahu has told the Biden administration he is willing to strike military rather than oil or nuclear facilities in Iran, according to two officials familiar with the matter, suggesting a more limited counterstrike aimed at preventing a full-scale war.
In the two weeks since Iran's latest missile barrage on Israel, its second direct attack in six months, the Middle East has braced for Israel's promised response, fearing the two countries' decades-long shadow war could explode into a head-on military confrontation. It comes at a politically fraught time for Washington, less than a month before the election, and President Joe Biden has said publicly he would <a href="https://www.washingtonpost.com/national/2024/10/02/biden-israel-iran-hezbollah-nuclear-sites/cc244502-80e7-11ef-90f2-d1fc6303655d_story.html?itid=lk_inline_manual_4">not support an Israeli strike on nuclear-related sites</a>.
When Biden and Netanyahu <a href="https://www.whitehouse.gov/briefing-room/statements-releases/2024/10/09/readout-of-president-joe-bidens-call-with-prime-minister-netanyahu-of-israel-9/">spoke Wednesday</a> — their <a href="https://www.washingtonpost.com/world/2024/10/09/netanyahu-biden-gallant-israel-iran/?itid=lk_inline_manual_5">first call</a> in more than seven weeks after months of rising tensions between the two men — the prime minister said he was planning to target military infrastructure in Iran, according to a U.S. official and an official familiar with the matter. Like others in this story, they spoke on the condition of anonymity to discuss sensitive deliberations.
The Israeli prime minister's office did not reply to a request for comment. The White House had no immediate comment.
&nbsp;
The retaliatory action would be calibrated to avoid the perception of "political interference in the U.S. elections," the official familiar with the matter said, signaling Netanyahu's understanding that the scope of the Israeli strike has the potential to reshape the <a href="https://www.washingtonpost.com/politics/2024/10/14/jewish-voters-pennsylvania-harris-trump-election-2024/?itid=lk_inline_manual_9">presidential race</a>.
An Israeli strike on Iranian oil facilities could send energy prices soaring, analysts say, while an attack on the country's nuclear research program could erase any remaining red lines governing Israel's conflict with Tehran, triggering further escalation and risking a more direct U.S. military role. Netanyahu's stated plan to go after military sites instead, as Israel did after Iran's attack in April, was met with relief in Washington.
Netanyahu was in a "more moderated place" in that discussion than he had previously been, said the U.S. official, describing the call between the two leaders. The apparent softening of the prime minister's stance factored into Biden's decision to send a powerful missile defense system to Israel, both officials said.
After that call, the president was more inclined to do it, the U.S. official said.
On Sunday, the Pentagon <a href="https://www.defense.gov/News/Releases/Release/Article/3934493/statement-by-pentagon-press-secretary-maj-gen-pat-ryder-on-the-deployment-of-a/">announced</a> that it was deploying its <a href="https://www.washingtonpost.com/national-security/2024/10/13/biden-thaad-missile-defense-israel/?itid=lk_inline_manual_15">anti-ballistic THAAD battery system</a> to Israel, along with around 100 U.S. military personnel. The system, which officials say is expected to arrive in the coming days, "underscores the United States' ironclad commitment to the defense of Israel," the Pentagon statement said.
&nbsp;
The Israeli strike on Iran would be carried out before the U.S. elections on Nov. 5, the official familiar with the matter said, because a lack of action could be interpreted by Iran as a sign of weakness. "It will be one in a series of responses," she said.
Zohar Palti, a former intelligence director for Mossad, said Netanyahu would need to balance Washington's appeals for moderation with the public demand in Israel for an overwhelming response.
"The Iranians have lost every measure of restraint that they used to have," he said. "Without the U.S. weapons, Israel cannot fight," Palti acknowledged. "But it is Israel who takes the risks" and "knows how to do the job."
On Thursday night, the official familiar with the matter said, Netanyahu convened his security cabinet for three hours to discuss the options on the table, but did not seek official authorization for the attack from his cabinet — keeping the timing intentionally open-ended.
Within the Israeli defense establishment, there is concern that the strike will not be forceful enough — or public enough — to deter Iran from another direct attack on Israel, or from developing nuclear weapons.
"The Israeli military wants to hit Iran's military leadership, because it doesn't hurt the people and it doesn't erupt the region into a larger war," said Gayil Talshir, a political scientist at Hebrew University who is in contact with senior members of Israel's defense establishment. "But that is not how Netanyahu is thinking."
In April, after a U.S.-led military coalition helped Israel intercept hundreds of Iranian drones and missiles — a <a href="https://www.washingtonpost.com/world/2024/04/13/iran-israel-drone-missile-attack/?itid=lk_inline_manual_27">large but well-choreographed attack</a> — Israel responded with a <a href="https://www.washingtonpost.com/world/2024/04/19/israel-iran-strike-isfahan/?itid=lk_inline_manual_27">pinpoint strike</a> on an air base in Isfahan, in central Iran. Israeli officials mostly kept quiet after the attack, with the exception of far-right National Security Minister Itamar Ben Gvir, who posted on social media that the response was "lame!"
On Oct. 1, after <a href="https://www.washingtonpost.com/world/2024/10/05/israel-mossad-hezbollah-pagers-nasrallah/?itid=lk_inline_manual_29">successful Israeli operations</a> against Iran and its proxies, including the <a href="https://www.washingtonpost.com/world/2024/09/29/hezbollah-nasrallah-lebanon-israel/?itid=lk_inline_manual_29">assassination of Hezbollah leader Hasan Nasrallah</a>, Tehran fired nearly 200 ballistic missiles at Israel — this time without warning — killing a Palestinian man in the West Bank and hitting at least two military installations. Amir Saeid Iravani, Iran's ambassador to the United Nations, said <a href="https://www.washingtonpost.com/world/2024/10/02/iran-israel-ballistic-missile-attack/?itid=lk_inline_manual_29">the attack</a> was meant to "restore balance and deterrence."
"When we responded last time, they didn't get the message," Palti said. "So the alternative now is between restraint or retaliation, and the answer is obvious."
But Israel is already fighting on multiple fronts. Late last month, thousands of Israeli troops <a href="https://www.washingtonpost.com/world/2024/10/02/israel-lebanon-invasion-hezbollah-war/?itid=lk_inline_manual_33">invaded southern Lebanon</a> for the first time in nearly two decades and, last week, the military unleashed yet another <a href="https://www.washingtonpost.com/world/2024/10/11/israel-gaza-north-hospitals-hamas/?itid=lk_inline_manual_33">punishing offensive in northern Gaza</a>. When it comes to Tehran, figures close to Netanyahu's team have signaled strategic patience.
"Just as we waited with [Hezbollah in] Lebanon, and with [Hamas in Gaza] in the south, now I think we will have to wait with Iran," Natan Eshel, an adviser to the Netanyahu family, said in a leaked message to Israeli media Sunday. "We will get to the same point in the north, we will finish it, and then get to Iran, which is not going anywhere."
On timing, too, Netanyahu appeared to be taking cues from Washington: The United States is "giving Israel and the Netanyahu government a bear hug, but for Hezbollah," said a former senior Israeli defense official who is familiar with current security discussions. "It is sending THAAD and promising all kinds of weapons that we need to finish off Hezbollah, saying that we can deal with Iran later."
While the White House has pushed unsuccessfully for a cease-fire in Gaza for months, leading to mounting friction between Netanyahu and Biden, it has so far given full backing to Israel's ground operations in Lebanon, even amid a growing international outcry over the civilian toll of the war and Israeli clashes with U.N. peacekeepers tasked with monitoring the border zone.
As part of consultations with the United States, the official familiar with the matter said, Israel has told Washington it intends to wrap up operations in Lebanon in the coming weeks.
Netanyahu's increased coordination with Washington comes after high-profile strikes carried out without advance warning to Israel's closest ally — including a <a href="https://www.washingtonpost.com/world/2024/04/01/syria-iran-embassy-strike-israel/?itid=lk_inline_manual_42">strike</a> on Iranian commanders near a diplomatic facility in Damascus, Syria, and the <a href="https://www.washingtonpost.com/world/2024/07/31/hamas-leader-assassinated-iran-israel/?itid=lk_inline_manual_42">assassination</a> of Hamas leader Ismail Haniyeh in Tehran — which surprised and angered U.S. officials.
While Netanyahu would continue to consult with U.S. officials on Israel's looming strike against Iran, he would not wait for a green light from Washington, said an Israeli official close to the prime minister.
"The person who will decide on the Israeli response to Iran will be [Netanyahu]," he said.
Hovering over the final decision are the complex, and interrelated, political dynamics in Washington and Tehran. Talshir, the political analyst, said Netanyahu's team was alarmed by the <a href="https://www.washingtonpost.com/world/2024/07/06/pezeshkian-iran-new-president/?itid=lk_inline_manual_45">recent election</a> of Iran's reformist president Masoud Pezeshkian, who has signaled an <a href="https://www.washingtonpost.com/world/2024/09/14/iran-engagement-russia-israel-pezeshkian/?itid=lk_inline_manual_45">openness</a> to reviving nuclear talks with the West. If Vice President Kamala Harris is elected, Netanyahu thinks the nuclear deal will be back on the table, she said, "and so now is a strategic moment to undermine this."
Prominent Israeli political figures, including former prime minister Naftali Bennett, continue to push for a direct attack on Iran's nuclear facilities. Anything less, he said, risked sacrificing the momentum Israel has gained from its wars in Lebanon and Gaza.
"Iran's proxies Hezbollah and Hamas both have drastically diminished capabilities," he said. "Israel has all the justification it could ever have. We have the ability. We have a once-in-a-lifetime opportunity."
 &nbsp;

Global

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

'Netanyahu Tells U.S. That Israel Will Strike Iranian Military, Not Nuclear Or Oil, Targets, Officials Say' - Washington Post

Legal

Press Releases

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Capstone Green Energy Corporation Investors with Losses to Secure Counsel Before Important December 12 Deadline in Securities Class Action – CGRN, CGRNQ

Small Cap

CGRN Investors Have Opportunity to Lead Capstone Green Energy Corporation Securities Fraud Lawsuit

CAPSTONE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Capstone To Contact Him Directly To Discuss Their Options

CGRN DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Capstone Green Energy Corporation Investors to Secure Counsel Before Important December 12 Deadline in Securities Class Action - CGRN, CGRNQ

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Capstone Green Energy Corporation (CGRN)

CAPSTONE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Capstone Green Energy Corporation and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capstone Green Energy Corporation - CGRNQ

CAPSTONE DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Capstone To Contact Him Directly To Discuss Their Options

CGRN DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Capstone Green Energy Corporation Investors to Secure Counsel Before Important December 12 Deadline in Securities Class Action – CGRN, CGRNQ

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Capstone Green Energy Corp

Capstone Green Energy Corp (CGRNQ) Forecast

Capstone Green Energy Corp (OTC:CGRNQ) Stock, Quote.Headers.trade-ideas